PubMed Health⌕ Search

PubMed · 15665346

Augmented trabeculectomy in paediatric glaucoma.

Abstract

AIMS: To report the experience with trabeculectomy augmented with mitomycin C and 5-fluorouracil for the treatment of paediatric glaucoma. METHODS: Retrospective, interventional case series design was used. The sample included 17 children (29 eyes) with primary (19 eyes) or secondary (10 eyes) glaucoma who were treated with augmented trabeculectomy as the primary procedure between 1990 and 2002. Data were collected on age and family history, preoperative and end of follow up intraocular pressure, cup/disc ratio (evaluated by drawing), visual acuity, complications, and post-surgery treatment. RESULTS: Patient age at surgery ranged from 1 month to 8 years; most patients (n = 14, 82.3%) were aged less than 1 year (range 1 month-8 months, mean 3.95 (SD 2.56) months); three patients (17.7%) were aged 3, 5, and 8 years. The duration of follow up was 3-120 months (mean 46 months). Intraocular pressure significantly improved from 21 mm Hg to 60 mm Hg (mean 33.1 (10) mm Hg) before surgery to 6-26 mm Hg (mean 17.1 (6) mm Hg) after, (p <0.0001). There was no significant change in cup/disc ratio: 0.1-0.8 (mean 0.42 (0.26)) before and 0.1-1.0 (mean 0.511 (0.27)) after (p = 0.45). In 22 eyes (75.8%), intraocular pressure was controlled at less than 20 mm Hg and the cup/disc ratio remained stable or improved. The life table success rate for intraocular pressure control remained stable at 86% at the 12, 24, and 36 months and after 48 months decreased to 53%. There was no significant difference in the life table results between primary and secondary glaucoma. 14 eyes (48.2%) had a visual acuity better than 20/120 by the end of follow up. Repeated surgery was necessary in eight eyes (27.5%), and additional antiglaucoma treatment in 13 (44.8%). Complications included retinal detachment 1 year after surgery, choroidal detachment, and blebitis (one eye each). CONCLUSIONS: Augmented trabeculectomy with mitomycin C and 5-fluorouracil may serve as the primary procedure in a selected group of paediatric patients with glaucoma.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Ehrlich, M Snir, M Lusky, D Weinberger, R Friling, D D Gaton. 2005. Augmented trabeculectomy in paediatric glaucoma.. https://doi.org/10.1136/bjo.2004.046037

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Biocompatibility of different barrier membranes in cultures of human CRL 11372 osteoblast-like cells: an immunohistochemical study.

OBJECTIVE: The aim of this study was to evaluate the biocompatibility of two different barrier materials in cultures of human osteoblast-like cells (CRL 11372) in vitro. MATERIAL AND METHODS: Polylactic acid (Epi-Guide; EG) and collagen membrane (Bio-Collagen, BC) were examined. To analyze the effect of materials on cell proliferation, cell numbers and cell viability, cells were cultured on the barrier membranes for 24 and 72 h. Cells plated on culture dishes (CD) served as positive controls. Cell proliferation rate was assessed by the bromodeoxyuridine (BrdU) immunohistochemical technique. The cell numbers of each well were counted. Cell viability was estimated by counting the number of cells, which excluded trypan blue solution. Scanning electron microscopy (SEM) was used to observe the interactions between osteoblastic cells and barrier membranes. RESULTS: The highest number of BrdU-labeled cells were seen on CD after both of the time periods. In comparison with the other two groups, BC showed significantly fewer cells after both time periods. Regarding cell numbers, after 24 and 72 h of incubations CD showed the highest number of cells. The number of viable cells was similar for all the groups. After 72 h for the EG group, SEM view showed flat cells. After 72-h time periods, the BC group revealed a weak adhesion of cells to the barriers. CONCLUSION: The results demonstrate that cells were able to proliferate on these materials and EG promoted the proliferation of human osteoblast like cells. We prefer to use the EG membrane.

Antimetabolites↗

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a novel group of ATP antagonists with moderate potency against CDK2-cyclin E. A preliminary SAR study based on 35 analogues suggests ways in which the pharmacophore could be further optimized, for example, via substitutions in the 4-aryl ring. Enzyme kinetics studies with the lead compound and X-ray crystallography of an inhibitor-CDK2 complex demonstrated that its mode of inhibition is competitive. Functional kinase assays confirmed the selectivity toward CDKs, with a preference for CDK9-cyclin T1. The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.

Antimetabolites↗

Synthesis of a technetium-99m labeled tricyclic ganciclovir analog for non-invasive reporter gene expression imaging.

A potential radiopharmaceutical and HSV1-TK substrate, 3-((1,3-dihydroxypropan-2-yloxy)-methyl)-6-(4-(3-((2-mercaptoethyl)(2-(2-mercaptoethyl-amino)-ethyl)amino)propoxy)phenyl)-3H-imidazopurin-9(5H)-one-oxo-technetium(V), was synthesized via a converging approach and its chemical structure was comparatively characterized with a non-radioactive analog. The final radiochemical purity and yield were 97 and 73%, respectively.

Antimetabolites↗